<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01034839</url>
  </required_header>
  <id_info>
    <org_study_id>mcazevedo01</org_study_id>
    <nct_id>NCT01034839</nct_id>
  </id_info>
  <brief_title>High-dose Cytarabine and Survival in AML</brief_title>
  <official_title>Role of Consolidation With High-dose Cytarabine in Overall Survival of Adults With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In adults with acute myeloid leukemia, especially those &lt; 60 years of age, high-dose&#xD;
      cytarabine consolidation therapy has been shown to influence survival, but the appropriate&#xD;
      dose has not been defined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background In adults with acute myeloid leukemia, especially those &lt; 60 years of age,&#xD;
      high-dose cytarabine consolidation therapy has been shown to influence survival. However, the&#xD;
      appropriate dose has not been defined. We evaluated survival after cytarabine consolidation&#xD;
      therapy at three different doses.&#xD;
&#xD;
      Design and Methods We conducted a single-center, retrospective study involving 499 acute&#xD;
      myeloid leukemia patients, aged 18-92 years, all evaluated between 1978 and 2007. Of those&#xD;
      499 patients, 400 received curative treatment and 203 received cytarabine consolidation. The&#xD;
      latter were divided into three groups: low-dose (receiving &lt; 1.5 g/m2 of i.v. cytarabine,&#xD;
      every 12 h, on 3 alternate days, for up to 4 cycles); medium-high-dose (&lt; 45.45 g-the median&#xD;
      dose-by the end of the cycles); and very-high-dose (â‰¥ 45.45 g by the end of the cycles).&#xD;
&#xD;
      Results Among the 400 patients receiving curative treatment, five-year survival was 22.8% (91&#xD;
      patients). Cytarabine consolidation dose was an independent determinant of survival&#xD;
      (significant differences were found among the groups), whereas age, karyotype, induction&#xD;
      protocol, French-American-British classification and etiology were not. In comparison with&#xD;
      the very-high-dose group, the risk of death was 3.871 times (95% CI, 1.043 to 14.370 times)&#xD;
      higher in the high-dose group (p=0.043) and 9.775 times (95% CI, 2.493 to 38.320 times)&#xD;
      higher in the low-dose group (p=0.001), assuming, in both cases, that age, karyotype,&#xD;
      French-American-British classification and etiology of acute myeloid leukemia were constant.&#xD;
&#xD;
      Conclusions Consolidation therapy with high-dose cytarabine appears to improve survival in&#xD;
      patients with acute myeloid leukemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">499</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>acute myeloid leukemia, adults</arm_group_label>
    <description>Adults treated for acute myeloid leukemia in our hospital between 1978 and 2007</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Acute myeloid leukemia in adults treated in the University of Sao Paulo between 1978 and&#xD;
        2007&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinical diagnosis of acute myeloid leukemia&#xD;
&#xD;
          -  age 18 years or above&#xD;
&#xD;
          -  must have been treated with potentially curative therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  children or age less than 18 years&#xD;
&#xD;
          -  palliative therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>92 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro ED Llacer, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05430010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2009</study_first_posted>
  <last_update_submitted>December 16, 2009</last_update_submitted>
  <last_update_submitted_qc>December 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Murilo Chermont Azevedo</name_title>
    <organization>University of Sao Paulo, General Hospital</organization>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>prognosis</keyword>
  <keyword>cytarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

